Urgences et Réanimation Pédiatrique, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, 59 Bd Pinel, 69677 Bron Cedex, France.
J Clin Virol. 2013 Sep;58(1):114-9. doi: 10.1016/j.jcv.2013.05.025. Epub 2013 Jul 3.
The emergence of novel A(H1N1)pdm2009 virus threatened to lead to frequent severe manifestations.
To describe the clinical, virological, and biological characteristics of the disease and identify the factors associated with severe presentations.
This prospective multicenter study recruited consecutive hospitalized patients with confirmed A(H1N1)pdm2009 disease. Clinical, virological and biological assessments were carried out at inclusion and 30 days post-inclusion. Disease manifestations were assessed by an adjudication committee using pre-identified definitions of complications and severity scores.
The study analyzed from November 30th, 2009 to February 8th, 2010, 40 hospitalized patients, 21 children and 19 adults. Eighteen (45%) were considered to have severe presentations. Except age, main characteristics in children and adults did not differ. The majority (18/21) of children and all adults had a respiratory presentation; extra-respiratory manifestations tended to be more frequent in children (12 vs. 6, P=0.10). Two children against 5 adults presented acute respiratory distress syndrome (ARDS, P=0.23), but more children suffered respiratory failure (7 vs. 1, P=0.046) without ARDS. At day 30, one death had occurred in each group. The main factor associated with non-severe presentation was an early (<48 h) implementation of oseltamivir treatment (P=0.038).
Although the study failed to achieve its main objective, due mainly to the difficulty of carrying a study of this nature in the midst of a pandemic, it allowed the description of a panel of unusual and complicated forms and confirmed the added value of early oseltamivir treatment in limiting severity in hospitalized children and adults.
新型 A(H1N1)pdm2009 病毒的出现可能导致频繁出现严重表现。
描述疾病的临床、病毒学和生物学特征,并确定与严重表现相关的因素。
这是一项前瞻性多中心研究,连续招募了确诊为 A(H1N1)pdm2009 疾病的住院患者。在纳入时和纳入后 30 天进行临床、病毒学和生物学评估。疾病表现由一个专门委员会使用预先确定的并发症和严重程度评分标准进行评估。
该研究于 2009 年 11 月 30 日至 2010 年 2 月 8 日进行,共分析了 40 名住院患者,其中 21 名儿童和 19 名成人。18 名(45%)被认为有严重表现。除了年龄,儿童和成人的主要特征没有差异。大多数(18/21)儿童和所有成人都有呼吸道表现;儿童更倾向于出现非呼吸道表现(12 例与 6 例,P=0.10)。2 例儿童出现急性呼吸窘迫综合征(ARDS),而 5 例成人出现 ARDS(P=0.23),但更多的儿童出现呼吸衰竭(7 例与 1 例,P=0.046)而无 ARDS。在第 30 天,每组都有 1 例死亡。非严重表现的主要相关因素是奥司他韦治疗的早期(<48 小时)实施(P=0.038)。
尽管该研究未能实现其主要目标,主要是由于在大流行期间开展此类研究的困难,但它描述了一系列不常见和复杂的表现形式,并证实了早期奥司他韦治疗在限制住院儿童和成人严重程度方面的附加值。